JBCHEPHARM at 20x FY23 EPS is a much safer and a better buy than a conventional FMCG Player like HINDUNILVR with no significant reinvestment moat and single digit earnings growth.

The difference here is that JB can still reinvest bulk of its cash flows at a similar/higher ROIIC.

More from Saket Reddy

You May Also Like